[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341875-105":59,"doc-detail-341875-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-experience-with-circulating-tumor-dna-in-cerebrospinal-fluid-from-patients-with-central-nervous-system-tumors-research-overview","Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors - Research overview","","Tumor genetic alterations are routinely characterized to classify disease more precisely and to guide targeted therapy selection. Cerebrospinal fluid (CSF) can provide circulating tumor DNA (ctDNA) in patients with central nervous system cancer. In 711 patients, comprehensive CSF ctDNA profiling using an FDA-authorized MSK-IMPACT platform in a hospital laboratory detected clinically relevant alterations in 489/922 (53.0%) CSF samples with documented CNS tumors. No ctDNA was detected in 85 CSF samples from patients without CNS tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-experience-with-circulating-tumor-dna-in-cerebrospinal-fluid-from-patients-with-central-nervous-system-tumors-research-overview/341875/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-experience-with-circulating-tumor-dna-in-cerebrospinal-fluid-from-patients-with-central-nervous-system-tumors-research-overview/341875.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was CSF circulating tumor DNA (ctDNA) profiled in the study?","Question",{"text":112,"@type":113},"The study performed comprehensive CSF ctDNA profiling in 711 patients using an FDA-authorized MSK-IMPACT platform in a hospital laboratory.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What ctDNA detection rate was observed in patients with clinically documented CNS tumors?",{"text":117,"@type":113},"Genetic alterations were identified in 489/922 (53.0%) CSF samples from patients with clinically documented CNS tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"How did ctDNA detection in patients without CNS tumors compare?",{"text":121,"@type":113},"None of the 85 CSF samples from patients without CNS tumors had detectable ctDNA.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341875,1790409209,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Hickman et al. Acta Neuropathologica  \nActa Neuropathologica Communications (2024) 12:151  \n[https://doi.org/10.1186/s40478-024-01846-4](https://doi.org/10.1186/s40478-024-01846-4 Communications)[ Communications](https://doi.org/10.1186/s40478-024-01846-4 Communications)  \n RESEARCH Open Access  \nReal-world experience with circulating  \ntumor DNA in cerebrospinal fluid from patients with central nervous system tumors  \nRichard A. Hickman 1,2,7 , Alexandra M. Miller3,4,8, Bridget M. Holle 1, Justin Jee5, Si‑Yang Liu5,  \nDara Ross2, Helena Yu5, Gregory J. Riely5, Christina Ombres2, Alexandra N. Gewirtz3, Anne S. Reiner6, Subhiksha Nandakumar1, Adam Price2, Thomas J. Kaley3, Maya S. Graham3, Chad Vanderbilt2, Satshil Rana2, Katherine Hill4, Kiana Chabot1, Carl Campos 1, Khedoudja Nafa2, Neerav Shukla4, Matthias Karajannis4, Bob Li5, Michael Berger2, Marc Ladanyi1,2, Elena Pentsova3, Adrienne Boire 1,3, A. Rose Brannon2, Tejus Bale2, Ingo K. Mellinghoff1,3* and Maria E. Arcila2*  \nAbstract  \nThe characterization of genetic alterations in tumor samples has become standard practice for many human cancers to achieve more precise disease classification and guide the selection of targeted therapies. Cerebrospinal fluid (CSF) can serve as a source of tumor DNA in patients with central nervous system (CNS) cancer. We performed comprehensive profiling of CSF circulating tumor DNA (ctDNA) in 711 patients using an FDA‑authorized platform (MSK‑IMPACT™) in a hospital laboratory. We identified genetic alterations in 489/922 (53 . 0%) CSF samples  \nwith clinically documented CNS tumors. None of 85 CSF samples from patients without CNS tumors had detectable ctDNA. The distribution of clinically actionable somatic alterations was consistent with tumor‑type specific alterations across the AACR GENIE cohort. Repeated CSF ctDNA examinations from the same patients identified clonal evolution and emergence of resistance mechanisms. ctDNA detection was associated with shortened overall survival following CSF collection. Next‑generation sequencing of CSF, collected through a minimally invasive lumbar puncture in a routine hospital setting, provides clinically actionable cancer genotype information in a large fraction of patients with CNS tumors.  \nRichard A. Hickman and Alexandra M. Miller are joint first authors.  \n*Correspondence: Ingo K. Mellinghoff [mellingi@mskcc.org](mellingi@mskcc.org)[ ](mellingi@mskcc.org)Maria E. Arcila [arcilam@mskcc.org](arcilam@mskcc.org)  \n1 Human Oncology and Pathogenesis Program, Sloan Kettering Institute, New York, NY 10065, USA  \n2 Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA  \n3 Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA  \n4 Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA  \n5 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA  \n6 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA  \n7 Present Address: Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, USA  \n8 Present Address: Department of Neurology, Perlmutter Cancer Center, NYU Langone Health and NYU Grossman School of Medicine, New York, NY 10016, USA  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not","cbCaihjB3iXYMQJf","https://ap.wps.com/l/cbCaihjB3iXYMQJf","pdf",5527214,13,"English","# Abstract\n# Introduction\n## Background on CNS tumors and clinical challenges\n## Tumor profiling and limitations of plasma liquid biopsy\n## Rationale for CSF-based ctDNA liquid biopsy","[{\"question\":\"How was CSF circulating tumor DNA (ctDNA) profiled in the study?\",\"answer\":\"The study performed comprehensive CSF ctDNA profiling in 711 patients using an FDA-authorized MSK-IMPACT platform in a hospital laboratory.\"},{\"question\":\"What ctDNA detection rate was observed in patients with clinically documented CNS tumors?\",\"answer\":\"Genetic alterations were identified in 489/922 (53.0%) CSF samples from patients with clinically documented CNS tumors.\"},{\"question\":\"How did ctDNA detection in patients without CNS tumors compare?\",\"answer\":\"None of the 85 CSF samples from patients without CNS tumors had detectable ctDNA.\"}]","Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors - Research overview | PDF",1790044235,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92d7c43101d6952db2b6e7832b00fee2.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4996a4306b7ce36ea4a5179e8ff0274.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d2de9f62aeb9f9d1983c2b45a2de2d4.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3256adc5745595072f1dd51b147c7201.webp",980,1301]